Early Ablation Therapy for the Treatment of Ischemic Ventricular Tachycardia in Patients With Implantable Cardioverter Defibrillators (ASPIRE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01557842|
Recruitment Status : Terminated
First Posted : March 20, 2012
Results First Posted : January 1, 2015
Last Update Posted : June 8, 2017
|Condition or disease||Intervention/treatment||Phase|
|Ventricular Tachycardia Ischemic||Drug: Drug Treatment Device: Catheter Ablation||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||15 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Early Ablation Therapy for the Treatment of Ischemic Ventricular Tachycardia in Patients With Implantable Cardioverter Defibrillators|
|Actual Study Start Date :||June 1, 2012|
|Actual Primary Completion Date :||March 19, 2014|
|Actual Study Completion Date :||March 19, 2014|
U.S. FDA Resources
Active Comparator: Treatment Group
This group receives radiofrequency catheter ablation and drug treatment.
Device: Catheter Ablation
Radiofrequency catheter ablation and Class I and III antiarrhythmic drug treatment.
Experimental: Control Group
This group receives only drug treatment.
Drug: Drug Treatment
Class I and III antiarrhythmic drug treatment.
- Percentage of Subjects Who Had Hospitalization for Ventricular Tachycardia (VT) Related Causes/Events [ Time Frame: From one month to 2 years follow up ]The hospital admission date must occur after completing the 1-month follow-up visit for the event to be considered an effectiveness failure.
- Cardiac-related Death [ Time Frame: 2 years follow up ]Subjects with cardiac-related death
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01557842
Show 23 Study Locations
|Study Chair:||David Callans, MD||University of Pennsylvania|
|Study Chair:||Francis Marchlinski, MD||University of Pennsylvania|
|Study Chair:||Andrea Natale, MD||Texas Cardiac Arrhythmia Research Foundation|
|Study Chair:||Vivek Reddy, MD||Icahn School of Medicine at Mount Sinai|
|Study Chair:||David Wilber, MD||Loyola University|